After Hours
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility.
Stocks Info
Roivant Sciences Ltd is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. The current market capitalization of Roivant Sciences Ltd is $14.08B. A total of 9.42 million shares were traded on the day, compared to an average of 7.86M shares.
In the most recent transaction, Venker Eric sold 200,000 shares of ROIV for 20.22 per share on Nov 07 ’25. After the transaction, the President & Immunovant CEO now owns 1,504,959 company shares. In a previous transaction on Nov 07 ’25, Venker Eric bought 200,000 shares at 20.22 per share.
Among the insiders who sold shares, Venker Eric disposed of 414,683 shares on Oct 15 ’25 at a per-share price of $16.93. This resulted in the President & Immunovant CEO holding 1,504,959 shares of ROIV after the transaction. In another insider transaction, Venker Eric sold 318,282 shares at $17.05 per share on Oct 16 ’25. Company shares held by the President & Immunovant CEO now total 1,504,959.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. In terms of 52-week highs and lows, ROIV has a high of $20.68 and a low of $8.73.
As of this writing, ROIV has an earnings estimate of -$0.3 per share for the current quarter. EPS was calculated based on a consensus of 4.0 estimates, with a high estimate of -$0.24 per share and a lower estimate of -$0.43. The company reported an EPS of -$0.3 in the last quarter
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. ROIV’s latest balance sheet shows that the firm has $2.06B in Cash & Short Term Investments as of fiscal 2022. There were $283.89M in debt and $184.37M in liabilities at the time. Its Book Value Per Share was $6.37, while its Total Shareholder’s Equity was $2.06B.
Analysts Opinion
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ROIV is Buy with a score of 4.69.
